Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy

Autores
Vargas Roig, Laura Maria; Cuello Carrión, Fernando Darío; Fernández-Escobar, Nicolás; Daguerre, Pedro; Leuzzi, Marcela; Ibarra, Jorge; Gago, Francisco E.; Nadin, Silvina Beatriz; Ciocca, Daniel Ramon
Año de publicación
2008
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
We have analyzed the predictive/prognostic value of Bcl-2 protein in breast cancer patients treated with neoadjuvant chemotherapy. One hundred and ten patients were submitted to two different chemotherapeutic regimens: a) 5-fluorouracil, adriamycin or epirubicin, and cyclophosphamide (FAC/FEC) during 2-6 cycles before surgery and 3 or 4 additional cycles of FAC/FEC after surgery (n = 40) and b) doxorubicin (D) 75 mg/m2 or epirubicin (E) 120 mg/m2 during 4 cycles before surgery, and 6 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after surgery (n = 70). Bcl-2 expression, evaluated by immunohistochemistry, did not change significantly after chemotherapy and was not related to clinical/pathological response. In FAC/FEC group, Bcl-2 positive expression after chemotherapy correlated with better disease free survival (DFS) and overall survival (OS) (P = 0.008 and P = 0.001). In D/E group, Bcl-2 also correlated with better DFS and OS (P = 0.03 and P = 0.054) in the post-chemotherapy biopsies. An unusual nuclear localization of Bax was observed in some biopsies, but this localization did not correlate with the tumor response or outcome of the patients. We found that a high Bcl-2 expression had no predictive value but had prognostic value in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.
Fil: Vargas Roig, Laura Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Cuello Carrión, Fernando Darío. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Fernández-Escobar, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Daguerre, Pedro. Hospital Luis Lagomaggiore, Mendoza; Argentina
Fil: Leuzzi, Marcela. Hospital Luis Lagomaggiore, Mendoza; Argentina
Fil: Ibarra, Jorge. Centro Oncológico de Integración Regional, Coir Mendoza; Argentina
Fil: Gago, Francisco E.. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina
Fil: Nadin, Silvina Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Ciocca, Daniel Ramon. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Materia
APOPTOSIS
BCL-2
BREAST CANCER
DOXORUBICIN
NEOADJUVANT CHEMOTHERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/81958
Acceder
id CONICETDig_dad054e04fa7ec0c81e019940de63767
oai_identifier_str oai:ri.conicet.gov.ar:11336/81958
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapyVargas Roig, Laura MariaCuello Carrión, Fernando DaríoFernández-Escobar, NicolásDaguerre, PedroLeuzzi, MarcelaIbarra, JorgeGago, Francisco E.Nadin, Silvina BeatrizCiocca, Daniel RamonAPOPTOSISBCL-2BREAST CANCERDOXORUBICINNEOADJUVANT CHEMOTHERAPYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3We have analyzed the predictive/prognostic value of Bcl-2 protein in breast cancer patients treated with neoadjuvant chemotherapy. One hundred and ten patients were submitted to two different chemotherapeutic regimens: a) 5-fluorouracil, adriamycin or epirubicin, and cyclophosphamide (FAC/FEC) during 2-6 cycles before surgery and 3 or 4 additional cycles of FAC/FEC after surgery (n = 40) and b) doxorubicin (D) 75 mg/m2 or epirubicin (E) 120 mg/m2 during 4 cycles before surgery, and 6 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after surgery (n = 70). Bcl-2 expression, evaluated by immunohistochemistry, did not change significantly after chemotherapy and was not related to clinical/pathological response. In FAC/FEC group, Bcl-2 positive expression after chemotherapy correlated with better disease free survival (DFS) and overall survival (OS) (P = 0.008 and P = 0.001). In D/E group, Bcl-2 also correlated with better DFS and OS (P = 0.03 and P = 0.054) in the post-chemotherapy biopsies. An unusual nuclear localization of Bax was observed in some biopsies, but this localization did not correlate with the tumor response or outcome of the patients. We found that a high Bcl-2 expression had no predictive value but had prognostic value in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.Fil: Vargas Roig, Laura Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Cuello Carrión, Fernando Darío. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Fernández-Escobar, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Daguerre, Pedro. Hospital Luis Lagomaggiore, Mendoza; ArgentinaFil: Leuzzi, Marcela. Hospital Luis Lagomaggiore, Mendoza; ArgentinaFil: Ibarra, Jorge. Centro Oncológico de Integración Regional, Coir Mendoza; ArgentinaFil: Gago, Francisco E.. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; ArgentinaFil: Nadin, Silvina Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Ciocca, Daniel Ramon. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaElsevier2008-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/81958Vargas Roig, Laura Maria; Cuello Carrión, Fernando Darío; Fernández-Escobar, Nicolás; Daguerre, Pedro; Leuzzi, Marcela; et al.; Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy; Elsevier; Molecular Oncology; 2; 1; 6-2008; 102-1111574-7891CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.molonc.2008.01.004info:eu-repo/semantics/altIdentifier/url/https://febs.onlinelibrary.wiley.com/doi/full/10.1016/j.molonc.2008.01.004info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:19:53Zoai:ri.conicet.gov.ar:11336/81958instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:19:54.062CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
title Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
spellingShingle Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
Vargas Roig, Laura Maria
APOPTOSIS
BCL-2
BREAST CANCER
DOXORUBICIN
NEOADJUVANT CHEMOTHERAPY
title_short Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
title_full Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
title_fullStr Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
title_full_unstemmed Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
title_sort Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
dc.creator.none.fl_str_mv Vargas Roig, Laura Maria
Cuello Carrión, Fernando Darío
Fernández-Escobar, Nicolás
Daguerre, Pedro
Leuzzi, Marcela
Ibarra, Jorge
Gago, Francisco E.
Nadin, Silvina Beatriz
Ciocca, Daniel Ramon
author Vargas Roig, Laura Maria
author_facet Vargas Roig, Laura Maria
Cuello Carrión, Fernando Darío
Fernández-Escobar, Nicolás
Daguerre, Pedro
Leuzzi, Marcela
Ibarra, Jorge
Gago, Francisco E.
Nadin, Silvina Beatriz
Ciocca, Daniel Ramon
author_role author
author2 Cuello Carrión, Fernando Darío
Fernández-Escobar, Nicolás
Daguerre, Pedro
Leuzzi, Marcela
Ibarra, Jorge
Gago, Francisco E.
Nadin, Silvina Beatriz
Ciocca, Daniel Ramon
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv APOPTOSIS
BCL-2
BREAST CANCER
DOXORUBICIN
NEOADJUVANT CHEMOTHERAPY
topic APOPTOSIS
BCL-2
BREAST CANCER
DOXORUBICIN
NEOADJUVANT CHEMOTHERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv We have analyzed the predictive/prognostic value of Bcl-2 protein in breast cancer patients treated with neoadjuvant chemotherapy. One hundred and ten patients were submitted to two different chemotherapeutic regimens: a) 5-fluorouracil, adriamycin or epirubicin, and cyclophosphamide (FAC/FEC) during 2-6 cycles before surgery and 3 or 4 additional cycles of FAC/FEC after surgery (n = 40) and b) doxorubicin (D) 75 mg/m2 or epirubicin (E) 120 mg/m2 during 4 cycles before surgery, and 6 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after surgery (n = 70). Bcl-2 expression, evaluated by immunohistochemistry, did not change significantly after chemotherapy and was not related to clinical/pathological response. In FAC/FEC group, Bcl-2 positive expression after chemotherapy correlated with better disease free survival (DFS) and overall survival (OS) (P = 0.008 and P = 0.001). In D/E group, Bcl-2 also correlated with better DFS and OS (P = 0.03 and P = 0.054) in the post-chemotherapy biopsies. An unusual nuclear localization of Bax was observed in some biopsies, but this localization did not correlate with the tumor response or outcome of the patients. We found that a high Bcl-2 expression had no predictive value but had prognostic value in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.
Fil: Vargas Roig, Laura Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Cuello Carrión, Fernando Darío. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Fernández-Escobar, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Daguerre, Pedro. Hospital Luis Lagomaggiore, Mendoza; Argentina
Fil: Leuzzi, Marcela. Hospital Luis Lagomaggiore, Mendoza; Argentina
Fil: Ibarra, Jorge. Centro Oncológico de Integración Regional, Coir Mendoza; Argentina
Fil: Gago, Francisco E.. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina
Fil: Nadin, Silvina Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Ciocca, Daniel Ramon. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
description We have analyzed the predictive/prognostic value of Bcl-2 protein in breast cancer patients treated with neoadjuvant chemotherapy. One hundred and ten patients were submitted to two different chemotherapeutic regimens: a) 5-fluorouracil, adriamycin or epirubicin, and cyclophosphamide (FAC/FEC) during 2-6 cycles before surgery and 3 or 4 additional cycles of FAC/FEC after surgery (n = 40) and b) doxorubicin (D) 75 mg/m2 or epirubicin (E) 120 mg/m2 during 4 cycles before surgery, and 6 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after surgery (n = 70). Bcl-2 expression, evaluated by immunohistochemistry, did not change significantly after chemotherapy and was not related to clinical/pathological response. In FAC/FEC group, Bcl-2 positive expression after chemotherapy correlated with better disease free survival (DFS) and overall survival (OS) (P = 0.008 and P = 0.001). In D/E group, Bcl-2 also correlated with better DFS and OS (P = 0.03 and P = 0.054) in the post-chemotherapy biopsies. An unusual nuclear localization of Bax was observed in some biopsies, but this localization did not correlate with the tumor response or outcome of the patients. We found that a high Bcl-2 expression had no predictive value but had prognostic value in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.
publishDate 2008
dc.date.none.fl_str_mv 2008-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/81958
Vargas Roig, Laura Maria; Cuello Carrión, Fernando Darío; Fernández-Escobar, Nicolás; Daguerre, Pedro; Leuzzi, Marcela; et al.; Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy; Elsevier; Molecular Oncology; 2; 1; 6-2008; 102-111
1574-7891
CONICET Digital
CONICET
url http://hdl.handle.net/11336/81958
identifier_str_mv Vargas Roig, Laura Maria; Cuello Carrión, Fernando Darío; Fernández-Escobar, Nicolás; Daguerre, Pedro; Leuzzi, Marcela; et al.; Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy; Elsevier; Molecular Oncology; 2; 1; 6-2008; 102-111
1574-7891
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.molonc.2008.01.004
info:eu-repo/semantics/altIdentifier/url/https://febs.onlinelibrary.wiley.com/doi/full/10.1016/j.molonc.2008.01.004
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083347559743488
score 13.22299

Publicaciones similares